Financial News

Financial Report: Mylan

$465 million DoJ settlement hits earnings

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Mylan 3Q Revenues: $3.1 billion (+13%) 3Q Loss: $119.8 million (earnings were $428.6 million 3Q15) YTD Revenues: $7.8 billion (+13%) YTD Earnings: $62.5 million (earnings were $653.1 million YTD15) Comments: Generics segment third party sales in the quarter were $2.6 billion, up 17%. Specialty segment sales were $418.7 million, down 4%. Loss in the quarter was primarily a result of the company’s $465 million settlement with the U.S. Department of Justice and other government agenc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters